A Study to Compare Eribulin Mesylate + Pertuzumab + Trastuzumab With Paclitaxel or Docetaxel + Pertuzumab + Trastuzumab

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

446 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-08-28

Study Completion Date

2024-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To verify that combination therapy with trastuzumab + pertuzumab + eribulin brings similar PFS and better QOL compared to trastuzumab + pertuzumab + taxane in advanced/recurrent HER2-positive breast cancer patients who have no medical history of chemotherapy except ado-trastuzumab emtansine

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Phase III Trial of Pertuzumab Retreatment in Previously Pertuzumab Treated Her2-Positive Advanced Breast Cancer

NCT02514681

HER2-positive Locally Advanced or Metastatic Breast Cancer

COMPLETED PHASE3

A Trial of Eribulin in Combination With HP Neoadjuvant Therapy in Patients With for HER2-Positive BC

NCT05945368

HER2-positive Breast Cancer

UNKNOWN PHASE2

Eribulin With Trastuzumab as First-line Therapy for Locally Recurrent or Metastatic HER2 Positive Breast Cancer

NCT01269346

Breast Cancer

COMPLETED PHASE2

SHR-A1811 Plus Pertuzumab in the Neoadjuvant Treatment of HER2 Positive BC

NCT06927180

Breast Cancer Early Stage Breast Cancer (Stage 1-3)

RECRUITING PHASE2

A Phase II/III Clinical Study to Evaluate the Efficacy and Safety of HLX87in Combination With HLX22 or Pertuzumab in the Neoadjuvant Therapy of HER2-Positive Bresat Cancer

NCT07294534

HER2 + Breast Cancer

NOT_YET_RECRUITING PHASE2/PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Breast Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Arm A

Trastuzumab + pertuzumab + Taxane\*

\*Taxane is chosen from the following; Docetaxel or Paclitaxel

Group Type ACTIVE_COMPARATOR

Pertuzumab

Intervention Type DRUG

Every 3 weeks

Trastuzumab

Intervention Type DRUG

Every 3 weeks

Docetaxel

Intervention Type DRUG

Every 3 weeks

Paclitaxel

Intervention Type DRUG

Every week

Arm B

Trastuzumab+ Pertuzumab + Eribulin

Group Type EXPERIMENTAL

Pertuzumab

Intervention Type DRUG

Every 3 weeks

Trastuzumab

Intervention Type DRUG

Every 3 weeks

Eribulin

Intervention Type DRUG

Administered for 2 weeks and is then stopped to be administered for 1 week

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Pertuzumab

Every 3 weeks

Intervention Type DRUG

Trastuzumab

Every 3 weeks

Intervention Type DRUG

Docetaxel

Every 3 weeks

Intervention Type DRUG

Paclitaxel

Every week

Intervention Type DRUG

Eribulin

Administered for 2 weeks and is then stopped to be administered for 1 week

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Perjeta Herceptin Taxotere Taxol Halaven

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Patients with breast cancer that is confirmed histologically or cytologically
2. Patients who are confirmed to be HER2 positive for the primary or a metastatic lesion at a participating medical institution
3. Patients with no medical history of treatment for advanced/recurrent cancer using a regimen of drugs including chemotherapeutics
4. \>=6 months have passed since perioperative treatment with anticancer agents
5. Presence of a measurable lesion not required
6. Female aged 20-70 years old at the time of consent acquisition
7. Baseline left ventricular ejection fraction (LVEF) measured by ECHO or MUGA of \>=50%
8. Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0-1
9. Patients who have maintained major organ functions, meeting all of the following criteria on a test within 28 days before enrollment. If there are multiple test results during this period, that obtained immediately before enrollment should be adopted.

(1) Neutrophil count: \>=1,500/mm3 (2) Platelet count: \>=100,000/mm 3 (3) Hemoglobin: \>=9.0 g/dL (4) Total bilirubin: \<=1.5 mg/dL (5) AST (GOT), ALT (GPT): \<=2.5 times the ULN (\<=5 times in those with liver metastasis) (6) Serum creatinine: \<=1.5 mg/dL 10) Patients with a life expectancy of at least 6 months 11) Patient who submits written consent herself after receiving sufficient explanation about this study 12) Patients who can undergo QOL investigation

Exclusion Criteria

1. Patients planning to undergo radical surgery if they respond to a treatment
2. Patients who have non-hematological adverse events assessed as Grade \>=3 in the Common Terminology Criteria for Adverse Events ver. 4.0 in the Japanese JCOG version (CTCAE v4.0-JCOG) at the time of enrollment
3. Patients who have symptomatic metastases to the central nervous system or whose symptoms are hard to control
4. Patients who have active double cancer
5. Patients who have poorly controlled hypertension, or unstable angina
6. Patients who have a past history of congestive heart failure assessed as Class ll or higher in the New York Heart Association (NYHA) classification, or clinically significant arrhythmia requiring treatment
7. Patients with a past history of myocardial infarction within 6 months before enrollment
8. Patients who are expected to undergo major surgical treatment or who had severe injury within 28 days before enrollment, or who require major surgical treatment during the study treatment period
9. Patients with interstitial pneumonia which is symptomatic or requires treatment
10. Pregnant women, those with a positive pregnancy test, and lactating women
11. Patients with active systemic infection (including HCV and HBV), or who are found to be HIV-positive
12. Patients with hypersensitivity against pertuzumab and trastuzumab
13. Patients whom the investigator consider unable or unwilling to follow the protocol requirements

Minimum Eligible Age

20 Years

Maximum Eligible Age

70 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No